Back to search results

Understanding Patient Experiences with Immunotherapy for Lung Cancer

This study is looking at how people with non-small cell lung cancer (NSCLC) feel about their intravenous (IV) immunotherapy treatments like Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, and Pembrolizumab. It wants to understand if patients find these treatments safe, convenient, comfortable, and smooth. The study also aims to see if patients would prefer to receive their immunotherapy as a shot under the skin (subcutaneous or SC) at home instead of through an IV at a clinic. They plan to gather information from 40 participants. This is an observational study, meaning you would complete surveys about your experiences. The study is currently unclear about its recruitment status.

Study design
This is an observational study involving about 40 participants. It is not a treatment study, but rather gathers information through surveys.
What's involved
You would complete surveys during the study, from when you start until up to one year later.
Compensation
Not stated in the trial record.
Follow-up
Your experiences will be measured from the start of the study until up to one year later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07339254

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Recruiting
Not specifiedAges 18+Observational
University of Southern California
~40 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy
Measured over At Baseline through study completion, up to 1 year.
+1 more outcome measured

Conditions

Lung Non-Small Cell Carcinoma

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

2 sites across 1 states
California2

Study leadership

  • Robert Hsu · PRINCIPAL_INVESTIGATOR · University of Southern California

Who to contact

Sandy Tran
[email protected]
323-865-3000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\* Age ≥ 18 years.
\* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
\* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
\* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion

\* Patients is unable to consent for themselves
\* Patient has not yet completed the 1st cycle of ICI-based therapy

What this trial measures

  • Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapyAt Baseline through study completion, up to 1 year.

    Outcome data will be collected using a questionnaire per study protocol. A Likert scale rating system of Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree will be used. Summaries of data will be descriptive and standard statistical methods (median) will be used to present the results. Pearson's chi-square test, the Mantel-Haenszel test (or corresponding exact tests, if resulting expected numbers are small) will be used; the resulting p-value will be used as an indication of strength of an observed association.

  • Patient interest in home SC ICI administration vs. IV ICI administration at the infusion centerAt Baseline through study completion, up to 1 year.

    Outcome data will be collected using a questionnaire per study protocol. Results will be summarized with point estimates and confidence intervals; p-values, when calculated, will be used to indicate the strength of an observed association (not just the magnitude).